USP Forms Collaboration with Russia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Forms Collaboration with Russia


ePT--the Electronic Newsletter of Pharmaceutical Technology

The United States Pharmacopeial (USP) Convention signed a memorandum of understanding (MOU) with the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor) last week in Moscow. Roszdravnadzor is the surveillance agency for medicines and medical supplies within Russia’s Ministry of Healthcare and Social Development.

Under the MOU, USP is collaborating with Roszdravnadzor for the first Russian translation of USP’s United States Pharmacopeia–National Formulary (USP–NF), which USP introduced last week at the XVI Russian Man and Drug National Congress. The Russian version of the compendia was translated and published by Geotar–Media, a publishing company in the Russian Federation known for its translations of medical works.

USP plans to publish a supplement to the book in 2010. At this time, the translation is current through USP 29 and NF 24, with ongoing plans to make the translation current.

Other potential areas of collaboration between the two groups under the MOU include:

  • Working relationships: Activities such as organizing joint annual scientific meetings, exchanging scientific staff, promoting pharmacopeial harmonization, promoting the use of modern laboratory standards and application of modern metrologic principles, and facilitating the exchange of information and taking action in cases of emergencies arising from accidental contamination or intentional adulteration of medicines and their ingredients
  • Reference materials: Development and use of reference materials for ensuring compliance to procedures described in compendia, including the USP–NF.
  • Third-party certification: Establishment of programs that
    allow review, testing, and auditing of manufacturers of pharmaceutical ingredients that are available in either the US or the Russian markets.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here